TELESTA THERAPEUTICS INC T.TST

Seeking Alpha

[beechguy]

With retooling of the indication to elicit a more favorable risk-benefit profile and/or a black box warning, I believe this drug can win FDA approval. I base this belief on the fact that most urologists on the board favored approval, while some board members stated they would opt for approval if the indication were narrowed to patients who could not/would not undergo cystectomy [10, 11]. In my opinion, the benefit outweighs the risk, given the niche market and the seemingly enthusiastic guidance from the FDA on page 45 regarding utilization of this drug in a certain patient subpopulation [12]. Consequently, I remain cautiously bullish on this company. Notwithstanding my optimistic navet, I believe the stock's battering after the ADCOM decision on November 16, 2015 has afforded a good buying opportunity. From the period November 17 to November 19, the stock lost almost 75% of its value. However, from November 25 to November 30, it has doubled, and now trades at $0.27. I suspect this recent rally to be a result of "fear wane," whereby investors are again focusing on the long term, despite the setback. From a strategic perspective, this small pharmaceutical has completed a Phase 3 clinical trial and is trading far below even a single dollar. To underscore this, note that Telesta has already signed a contract with Ipsen, which includes a $10 million upfront payment to market the drug throughout most of the remainder of the world [13]. To me, Telesta is the epitome of undervaluation, especially considering its product can still make it to most other patients on the planet! However, don't discount the company's chances in the United States. Coupled with a first quarter financial statement of roughly $40 million in cash and liquid securities, and a burn rate of $1.3 million per month, and you see there is plenty of time to elbow into the US market (amounts in Canadian Dollars) [14]. Perhaps another, larger enterprising pharmaceutical is scrutinizing this fascinoma too?

[Frogger2]

This is a great article Beech, the most thorough I've seen. Here's more but not all for your reading pleasure, In Radiology, a colloquial term some used to describe an unexpected, interesting finding is fascinoma. This term applies quite well to the plucky, Montreal-based pharmaceutical company Telesta Therapeutics (OTCPK:BNHLF), as I believe that despite their recent setback, BNHLF

[DamnYankees]

Beech, Sy and Frogger, I am fine if you gentlemen would like to re assert control of the dialogue but shorten your sentences, separate your paragraphs and seek the assistance of bullet points. think effective writing when constructing a post. No one wants to read Tolstoy on the weekend. Be short and be concise. The investors that you are attempting to sway are dumber than you give them credit for.

[Frogger2]

Thanks for the feedback Yank, you may need to check your setup on devices. This is an article from SA and displayes perfectly on all my devices including paragraph split, bullets etc. It's very well written and full of information. I know the information is not for all on this board, it's really for people looking for information; opinions and willing to take the time to read. The loons

[DamnYankees]

Frogger, I could be mistaken but I thought that I have commented on the positive tone of the young man from Seeking Alpha. I think it may have been yesterday. Maybe you need to be reminded that it is not people from your bullboard who chose to send the scientist to your FDA review.  While the C Suite watched from afar as their Adcomm went up in smoke and 70% of the company value was wiped out

[Frogger2]

Once again a totally unrelated response.  It's a article with opinion, it has no relation to who attended the Adcom. Ignore

[DamnYankees]

Thank You for the ignore Frogger, Fortunately you were not the intended recipient. My post was a  general commentary on the effort here to deflect balme away from what happened at the Adcomm debacle, and subsequent elimination of 70% of shareholder equity in Telesta Therapeutics. Keep on trucking Frogger!